Cross-study hierarchical modeling of stratified clinical trial data.
暂无分享,去创建一个
J S Hodges | B P Carlin | B Johnson | B. Carlin | J. Hodges | B. Johnson
[1] A E Gelfand,et al. Approaches for optimal sequential decision analysis in clinical trials. , 1998, Biometrics.
[2] D J Sargent,et al. A general framework for random effects survival analysis in the Cox proportional hazards setting. , 1998, Biometrics.
[3] J. Neaton,et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, The New England journal of medicine.
[4] R. Littell. SAS System for Mixed Models , 1996 .
[5] J P Matts,et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, The Journal of infectious diseases.
[6] Adrian F. M. Smith,et al. Sampling-Based Approaches to Calculating Marginal Densities , 1990 .
[7] T. Louis,et al. A randomized, placebo‐controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV‐infected individuals , 1998 .
[8] W. El-Sadr,et al. Weekly Fluconazole for the Prevention of Mucosal Candidiasis in Women with HIV Infection , 1997, Annals of Internal Medicine.
[9] H. Akaike,et al. Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .
[10] G. Schwarz. Estimating the Dimension of a Model , 1978 .
[11] K. Larntz,et al. Data analysis issues for protocols with overlapping enrollment. , 1996, Statistics in medicine.
[12] Bradley P. Carlin,et al. BAYES AND EMPIRICAL BAYES METHODS FOR DATA ANALYSIS , 1996, Stat. Comput..
[13] Thomas A. Louis,et al. Meta-Analysis for Explanation: A Casebook. , 1992 .
[14] G. Casella,et al. Explaining the Gibbs Sampler , 1992 .
[15] B. Carlin,et al. Hierarchical Proportional Hazards Regression Models for Highly Stratified Data , 1999, Biometrics.
[16] Purushottam W. Laud,et al. Predictive Model Selection , 1995 .
[17] K Abrams,et al. Approximate Bayesian inference for random effects meta-analysis. , 1998, Statistics in medicine.
[18] Sylvia Richardson,et al. Markov Chain Monte Carlo in Practice , 1997 .
[19] Alan E. Gelfand,et al. Model choice: A minimum posterior predictive loss approach , 1998, AISTATS.
[20] D K Stangl,et al. Prediction and decision making using Bayesian hierarchical models. , 1995, Statistics in medicine.
[21] W. Gilks,et al. Adaptive Rejection Sampling for Gibbs Sampling , 1992 .
[22] B P Carlin,et al. Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[23] D J Spiegelhalter,et al. Comparison of Bayesian with group sequential methods for monitoring clinical trials. , 1989, Controlled clinical trials.
[24] David J. Spiegelhalter,et al. Bayesian Approaches to Randomized Trials , 1994, Bayesian Biostatistics.
[25] D A Berry,et al. A case for Bayesianism in clinical trials. , 1993, Statistics in medicine.
[26] Jianming Ye. On Measuring and Correcting the Effects of Data Mining and Model Selection , 1998 .
[27] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[28] J Hornberger,et al. The cost-benefit of a randomized trial to a health care organization. , 1998, Controlled clinical trials.
[29] C. Pettinelli,et al. Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter , 1996 .
[30] David S. Cordray,et al. Meta-Analysis for Explanation , 1994 .
[31] M D Hughes,et al. Evaluating surrogate markers. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.